Document is current
Any future updates will be listed below
-
Authors
de Albuquerque, Lucas Zanetti
da Silva, Jessé Lopes
Rodrigues, Fabiana Resende
Fernandes, Priscila Valverde
Small, Isabele Ávila
Leite, Luís Felipe
Guitmann, Gustavo
de Melo, Andreia Cristina
- License Information
-
More Information
Article History
Received: 14 August 2025
Accepted: 5 November 2025
First Online: 25 November 2025
Declarations
:
: Ethics approval was obtained from the Institutional Review Board (Ethics Committee for Human Research of the Brazilian National Cancer Institute), under registration number 03727818.2.0000.5274. The study was conducted in accordance with the Good Clinical Practice (GCP) guidelines established by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). It was also aligned with core principles from the 2000 version of the Declaration of Helsinki, as referenced by Brazilian Resolution No. 466/2012 of the National Health Council, which regulates research involving human subjects in Brazil. Given the retrospective observational design of this study, the committee waived the requirement for obtaining informed consent from all participants.
: Not applicable.
: ACM has received grants or contracts from Amgen, AstraZeneca, Bristol Myers Squibb, Clovis Oncology, GSK, MSD, Novartis, Pierre Fabre, Regeneron Pharmaceuticals, and Roche, with payments made to the institution. ACM also reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Adium, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, GSK, MSD, Novartis, and Roche. The other authors declare that they have no conflicts of interest.
